PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8391894

Small cell lung cancer.

J A Hinson·M C Perry
View original source ↗Export metadata ↓

Abstract

Small cell lung cancer is a unique form of lung cancer characterized by rapid growth, dissemination at diagnosis, and responsiveness to both radiotherapy and chemotherapy. It accounts for about one quarter of all lung cancers and, left untreated, results in the shortest survival of any pulmonary neoplasm, with a median survival of two to four months. This article reviews the epidemiology, pathology, clinical characteristics, staging, and treatment of this disease.

Explore related subjects

Carcinoma, Small CellHumansLung NeoplasmsPrognosisJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J A Hinson, M C Perry. Small cell lung cancer.. https://doi.org/10.3322/canjclin.43.4.216

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.

The topoisomerase I inhibitor, topotecan, is approved for the treatment of recurrent small-cell lung cancer (SCLC) and ovarian cancer (OC). Patients with recurrent SCLC and OC typically experience multiple relapses and receive multiple rounds of chemotherapy. In these settings, disease stabilisation is considered a treatment benefit, and quality-of-life effects and cumulative toxicities of treatments should be considered. Many patients with recurrent cancer may be predisposed to treatment-related adverse events because of advanced age, renal impairment or extensive prior therapy. The standard regimen of topotecan, 1.5 mg/m(2) on days 1-5 of a 21-day cycle, has generally mild nonhaematological toxicity and a well-defined haematological toxicity profile characterised by reversible and noncumulative neutropenia. Alternative regimens may lower the incidence of haematological toxicities and maintain antitumour efficacy. Topotecan may provide physicians with a versatile therapeutic option for the treatment of patients with relapsed SCLC or OC.

Carcinoma, Small Cell↗